6.31
-0.03(-0.47%)
Currency In USD
| Previous Close | 6.34 |
| Open | 6.18 |
| Day High | 6.5 |
| Day Low | 6.13 |
| 52-Week High | 12.46 |
| 52-Week Low | 1.15 |
| Volume | 75,236 |
| Average Volume | 71,260 |
| Market Cap | 44.13M |
| PE | -3.41 |
| EPS | -1.85 |
| Moving Average 50 Days | 4.36 |
| Moving Average 200 Days | 2.89 |
| Change | -0.03 |
If you invested $1000 in Minerva Neurosciences, Inc. (NERV) 10 years ago, it would be worth $157.75 as of February 21, 2026 at a share price of $6.31. Whereas If you bought $1000 worth of Minerva Neurosciences, Inc. (NERV) shares 5 years ago, it would be worth $226 as of February 21, 2026 at a share price of $6.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
GlobeNewswire Inc.
Jan 26, 2026 12:00 PM GMT
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it w
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
GlobeNewswire Inc.
Nov 19, 2025 1:30 PM GMT
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appoi
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
GlobeNewswire Inc.
Oct 21, 2025 12:00 PM GMT
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 mil